Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first in human study of PB6440

Next Previous
Trial Profile

A first in human study of PB6440

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 20 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JX-09 (Primary)
  • Indications Hypertension
  • Focus Adverse reactions; First in man

Most Recent Events

  • 12 Aug 2022 According to an PhaseBio Pharmaceuticals media release, the company expects to file our IND for PB6440 in the first half of 2023 and to initiate first-in-human trials in mid-2023.
  • 20 Jan 2020 New trial record
  • 13 Jan 2020 According to an PhaseBio Pharmaceuticals media release, the company is planning to initiate clinical development of PB6440 pending the completion of nonclinical Investigational New Drug Application (IND)-enabling studies planned for 2020, which are expected to be followed by an IND filing and a first-in-human study in early 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top